Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac Vaccine

Kuan, Jew Win and Tan, Cheng Siang and Anselm, Su Ting and Vaenessa, Noni and Whilemena Upam, Herman Ulok Melina and Ummi Syafiqah, Abdorahman and Joseph Niler, Bimbang and Lela, Suut and Asri, Said (2022) Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac Vaccine. Asia Pacific Journal of Public Health. pp. 1-3. ISSN 1941-2479

PDF Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac Vaccine.pdf Download (96kB)

Abstract

Dear Editor Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm characterized by an oncogenic fusion gene, BCR-ABL1. Most CML patients present at chronic phase, ~90%,1 when BCR-ABL1 tyrosine kinase inhibitor (TKI) is the recommended first-line treatment. Antibody response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in CML patients is concerned due to probable CML-induced and/or TKI-induced immunosuppression. To our knowledge, two studies reported antibody response post-SARS-CoV-2 vaccine in CML patients.2,3 A study reported anti-spike SARS-CoV-2 IgG (IgG-S) responses > 14 days after a dose of Comirnaty (Comirnaty or BNT162b2, Pfizer-BioNTech) (n = 1) or ChAdOx1 (ChAdOx1 nCoV-19 or AZD1222, AstraZeneca-Oxford) (n = 11) vaccine.2 Seroconversion rate post-ChAdOx1 was lower than control group, 8/11 (73%) versus 58/63 (92%).2 A study reported response 3 weeks after a dose of Comirnaty (n = 16) using a different laboratory methodology.3

Actions (For repository members only: login required)

View Item